Breast Cancer

Triple-negative breast cancer is considered one of the most difficult to treat breast cancers, with few treatment options, but finally a breakthrough study shows progress by extending patient survival. Read More ›


Metastatic estrogen receptor (ER)-positive breast cancer responds well to anti-ER therapies, but eventually resistance occurs and the drugs fail to work. A new study presented at the 2018 AACR meeting suggests that HER2 mutations can be acquired during metastatic cancer and their development represents a previously unreported mechanism of resistance to treatment. Read More ›




This week Sellas Life Sciences Group announced data from a study of NeuVax (nelipepimut-S) in combination with Herceptin (trastuzumab) in patients with HER2 1+/2+ breast cancer. Read More ›



The Mechanism of Action of CDK4/6 Inhibitors
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer. Read More ›

Page 5 of 8

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: